COMPOSITION A white or yellowish-white injectable suspension containing 50 mg/ml ceftiofur (as hydrochloride).

 

PHARMACOLOGICAL PROPERTIES

Farmakodinamik Ceftiofur is a third-generation cephalosporin and is effective against most Gram-positive and Gram-negative bacteria. Ceftiofur acts by inhibiting bacterial cell wall synthesis. Beta-lactams exert their effect by interfering with the synthesis of the bacterial cell wall. Cell wall synthesis is dependent on enzymes called penicillin-binding proteins (PBPs). Bacteria develop resistance to cephalosporins through four primary mechanisms: 1) by desensitizing penicillin-binding proteins, 2) by altering the beta-lactam permeability of the cell wall, 3) by producing beta-lactamases that split the beta-lactam ring, and 4) via active efflux. Some beta-lactamases found in Gram-negative enteric organisms can variably increase the MIC (Minimum Inhibitory Concentration) values of first and second-generation cephalosporins, beta-lactam inhibitor combinations, penicillins, ampicillins, and third and fourth-generation cephalosporins.

 

INDICATIONS / FIELD OF USE

Treatment of the following infections in cattle caused by bacteria sensitive to ceftiofur:

• Respiratory tract infections caused by strains of Mannheimia haemolytica (formerly Pasteurella haemolytica), Pasteurella multocida, and Histophilus somni (formerly Haemophilus somnus),
• Acute interdigital necrobacillosis (panaritium, foot rot) caused by Fusobacterium necrophorum and Bacteroides melaninogenicus (Porphyromonas asaccharolytica),
• Acute post-partum (puerperal) metritis occurring within 10 days after calving, caused by Escherichia coli, Arcanobacterium pyogenes, and Fusobacterium necrophorum, where treatment with other antibiotics has failed.

 

DOSAGE AND ADMINISTRATION

Before use, shake the vial vigorously for no more than 60 seconds or until the product is sufficiently suspended. To ensure correct dosage, the body weights of the animals should be measured as accurately as possible. No more than 7 ml should be injected into a single injection site. Injections on different days should be administered at different sites.

• Respiratory system infections: 1 mg/kg body weight daily for 3-5 days via subcutaneous route (1 ml of product per 50 kg body weight daily).
• Acute interdigital necrobacillosis: 1 mg/kg body weight daily for 3 days via subcutaneous route (1 ml of product per 50 kg body weight daily).
• Acute post-partum metritis (within 10 days after calving): 1 mg/kg body weight daily for 5 days via subcutaneous route (1 ml of product per 50 kg body weight daily). In some cases of this infection, supportive therapy may be required.